Table 1.
Pathogen | Key characteristics of animal challenge model |
Immunological end points/assays | Bridging animal data to human | Animal studies predictive of vaccine protection against disease in humans | ||
---|---|---|---|---|---|---|
Pathogen challenge stock (human; animal prototype) | Disease pattern similar to humans | Correlate of protection identified | Species-independent assay available | |||
HPV | Animal pathogen prototypes (bovine, dog) | Partially | Yes | No | Yes | Yes |
Anthraxa | Human pathogen/validated | Yes | Yes | Yes/validated | Yes | Yes |
Ebola | Human pathogen | Yes | Partially | Not finalized; not validated |
No | Partially |
HIV | Animal pathogen prototypes (SIV, SHIV) | Partially | No | No | No | No |
HPV, Human papillomavirus; SIV, simian immunodeficiency virus; SHIV, HIV strain.
aAnthrax vaccine was approved under the FDA “Animal Rule.”